Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

DMD-focused Solid Biosciences nets $133.7mm in IPO

Executive Summary

Duchenne muscular dystrophy (DMD)-focused therapeutics firm Solid Biosciences Inc. netted $133.7mm in its initial public offering of 9mm shares (including the overallotment) at $16. Earlier this month, the company first announced plans to offer 5.9mm shares at a $16-18 range, later upping that to 7mm shares at an $18-19 range, before it priced at $16.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies